HC Wainwright Has Positive Estimate for TSE:BCT Q2 Earnings

BriaCell Therapeutics Corp. (TSE:BCT) – Equities research analysts at HC Wainwright boosted their Q2 2025 EPS estimates for BriaCell Therapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($2.83) per share for the quarter, up from their prior estimate of ($5.70). HC Wainwright also issued estimates for BriaCell Therapeutics’ Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($3.57) EPS, FY2026 earnings at ($2.14) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.01) EPS and FY2029 earnings at ($0.35) EPS.

BriaCell Therapeutics Stock Performance

Shares of BriaCell Therapeutics stock opened at C$5.97 on Wednesday. The stock has a market cap of C$213.96 million, a PE ratio of -11.94 and a beta of 1.83. The firm has a 50-day moving average of C$1.55 and a 200-day moving average of C$1.20. BriaCell Therapeutics has a 52-week low of C$5.68 and a 52-week high of C$86.85.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.